Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAntibody characterization is important in research and biopharmaceutical development. All therapeutic proteins produced from current technologies have heterogeneities in the final product because various modifications occur during different stages of production. Due to these heterogeneities, thorough characterization is necessary for the reproducible and safe production of therapeutic proteins.
At Creative Biolabs, antibodies can be completely characterized using a variety of techniques.
Monoclonal antibodies and antibody drug conjugates (ADCs) are one of the most active areas of biologic drug therapies. Thanks to changes in the regulatory framework in the U.S., an increasing number of new monoclonal antibody (mAb) drug therapies are now entering commercial clinical trials. This trend is creating a strong demand for reliable, fast and efficient solutions for mAb characterization.
The basic mAb characterization workflows consist of the following types of analysis:
• Molecular weight determination of intact and reduced protein
• Peptide mapping
• Co- and post-translational modification mapping
• Acquired non-biological modifications
• Disulfide bond mapping
In addition, monoclonal and polyclonal antibody binding affinities can be characterized by Simple Western analysis. Relative specificity of the antibody to the target protein of interest can be monitored. Antibody clonal screening can be performed using nanoliter amounts of material.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
